Trial Profile
Dendritic cells loaded with allogeneic tumor cell lysate (PheraLys) in surgically resected pancreatic cancer patients (REACtiVe Trial)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Autologous dendritic cell vaccine Amphera (Primary) ; Autologous dendritic cell vaccine Amphera (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms REACtiVe
- 21 Nov 2023 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 According to an Amphera media release, the company announces that the EMA Committee for Orphan Medicinal Products (COMP) has recommended the granting of orphan medicinal product designation for MesoPher in pancreatic cancer.
- 12 Dec 2022 Results published in the Amphera Media Release